Skip to Main Content
Table 1.

Patient and tumor characteristics (n = 74)

CharacteristicNumber of patients, n (%)
Median age, y (range) 49 (27-73) 
Ethnicity  
    White 46 (62) 
    Black 8 (11) 
    Hispanic 17 (23) 
    Asian 3 (4) 
Histologic type  
    Invasive ductal 66 (90) 
    Invasive lobular 4 (5) 
    Mixed ductal and lobular 4 (5) 
T classification at diagnosis  
    T1 10 (14) 
    T2 37 (50) 
    T3 12 (16) 
    T4 15 (20) 
N classification at diagnosis  
    N0 16 (22) 
    N1 33 (45) 
    N2 12 (16) 
    N3 13 (17) 
Nuclear grade  
    1 or 2 36 (49) 
    3 38 (51) 
Estrogen receptor status  
    Positive 46 (62) 
    Negative 28 (38) 
HER2 status  
    Positive 11 (15) 
    Negative 63 (85) 
Neoadjuvant chemotherapy  
    T weekly × 4 + FAC × 4 65 (88) 
    T thrice/week × 4 + FAC × 4 9 (12) 
CharacteristicNumber of patients, n (%)
Median age, y (range) 49 (27-73) 
Ethnicity  
    White 46 (62) 
    Black 8 (11) 
    Hispanic 17 (23) 
    Asian 3 (4) 
Histologic type  
    Invasive ductal 66 (90) 
    Invasive lobular 4 (5) 
    Mixed ductal and lobular 4 (5) 
T classification at diagnosis  
    T1 10 (14) 
    T2 37 (50) 
    T3 12 (16) 
    T4 15 (20) 
N classification at diagnosis  
    N0 16 (22) 
    N1 33 (45) 
    N2 12 (16) 
    N3 13 (17) 
Nuclear grade  
    1 or 2 36 (49) 
    3 38 (51) 
Estrogen receptor status  
    Positive 46 (62) 
    Negative 28 (38) 
HER2 status  
    Positive 11 (15) 
    Negative 63 (85) 
Neoadjuvant chemotherapy  
    T weekly × 4 + FAC × 4 65 (88) 
    T thrice/week × 4 + FAC × 4 9 (12) 

Abbreviation: FAC, 5-fluorouracil, doxorubicin, and cyclophosphamide, given in a 28-d cycle.

Close Modal

or Create an Account

Close Modal
Close Modal